Abstract: This disclosure relates to methods of managing cancer and tumor growth. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering a combination of chemotherapy agents, wherein a first chemotherapy agent is capable of inhibiting oxidative phosphorylation of pyruvate and a second chemotherapy agent is capable of inhibiting glucose metabolism. In certain embodiments, the first and second chemotherapy agents are administered in combination with an additional chemotherapy agent.

Abstract: In certain embodiments, this disclosure relates to method of treating and diagnosing cancer by administering a Bcl-2 inhibitor optionally in combination with a mitochondrial complex II inhibitor. In certain embodiments, a subject is diagnosed with, exhibiting symptoms of, or at risk of cancer wherein the cancer is a hematological malignancy such as multiple myeloma, leukemia, or lymphoma.

Abstract: In certain embodiments, this disclosure relates to methods of treating cancer comprising administering an electron transport chain complex I inhibitor and/or a complex II succinate ubiquinone reductase (SQR) inhibitor in combination with another anticancer agent such as a BCL-2 antagonist or proteasome inhibitor. In certain embodiments, the cancer is a hematological cancer such as multiple myeloma, chronic lymphocytic leukemia, or acute myeloid leukemia. In certain embodiments, the treatment is under low glucose or fasting conditions.

Abstract: In certain embodiments, this disclosure relates to method of treating and diagnosing cancer by administering a Bcl-2 inhibitor optionally in combination with a mitochondrial complex II inhibitor. In certain embodiments, a subject is diagnosed with, exhibiting symptoms of, or at risk of cancer wherein the cancer is a hematological malignancy such as multiple myeloma, leukemia, or lymphoma.

Abstract: This disclosure relates to GLUT 4 inhibitors and uses as chemotherapy agents. In certain embodiments, this disclosure relates to methods of treating or preventing cancer comprising administering an effective amount of a GLUT 4 inhibitor disclosed herein to a subject in need thereof. In certain embodiments, the GLUT 4 inhibitor has Formula (I), prodrugs, derivatives, or salts thereof wherein the substituents are reported herein. In certain embodiments, the GLUT 4 inhibitor is N-(3-(4-fluorophenethoxy)benzyl)-2-(4-methoxyphenyl)-N-(pyridin-4-ylmethyl)acetamide or salts thereof.

Abstract: Disclosed herein are methods of treating, diagnosing, and prognosing GLUT-dependent cancers and OXPHOS-dependent cancers. In some embodiments, the methods comprise administering to a patient in need thereof a GLUT inhibitor and/or an OXPHOS inhibitor. The inhibitors may be administered before, concurrently, or after one another. Suitable GLUT-dependent cancers may include a GLUT4-dependent cancer, a GLUT8-dependent cancer, and a GLUT11-dependent cancer. Suitable GLUT inhibitors may include a GLUT4 inhibitor, a GLUT8 inhibitor, and a GLUT11 inhibitor. Suitable OXPHOS-dependent cancers may include mitochondrial OXPHOS-dependent cancers, including cancers that have developed resistance to treatment with a GLUT-inhibitor.

Abstract: This disclosure relates to treating or preventing cancers, such as hematological malignancies, by administering a compound that binds BCL2 and one or more compounds that inhibit glucose or glutamine metabolism. In certain embodiments, the compounds that inhibit glucose metabolism are ritonavir optionally in combination with 6-diazo-5-oxo-L-norleucine or any derivative, prodrugs, or salts of these compounds. Contemplated BCL2 binding compounds are ABT-199 (venetoclax), ABT-263 (navitoclax), or ABT-737.

Abstract: Methods of treating cancer comprising administering inhibitors of glucose transporters (GLUTs) are provided. Methods of predicting whether a cancer will respond to treatment with a GLUT inhibitor also are provided.

Abstract: Disclosed herein are methods of treating, diagnosing, and prognosing GLUT-dependent cancers and OXPHOS-dependent cancers. In some embodiments, the methods comprise administering to a patient in need thereof a GLUT inhibitor and/or an OXPHOS inhibitor. The inhibitors may be administered before, concurrently, or after one another. Suitable GLUT-dependent cancers may include a GLUT4-dependent cancer, a GLUT8-dependent cancer, and a GLUT11-dependent cancer. Suitable GLUT inhibitors may include a GLUT4 inhibitor, a GLUT8 inhibitor, and a GLUT11 inhibitor. Suitable OXPHOS-dependent cancers may include mitochondrial OXPHOS-dependent cancers, including cancers that have developed resistance to treatment with a GLUT-inhibitor.

Abstract: Methods of treating cancer comprising administering inhibitors of glucose transporters (GLUTs) are provided. Methods of predicting whether a cancer will respond to treatment with a GLUT inhibitor also are provided.